skip to content
Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis.
ClosePreview this item
Checking...

Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis.

Author: C Schmidt-Lauber Affiliation: Experimental Nephrology, Department of Internal Medicine D, University Hospital Münster, Münster, Germany.S HarrachT PapM FischerM VictorAll authors
Edition/Format: Article Article : English
Publication:PloS one, 2012; 7(12): e52247
Other Databases: WorldCat
Summary:
BACKGROUND: Tyrosine kinase inhibitors (TKIs) are effective in treating malignant disorders and were lately suggested to have an impact on non-malignant diseases. However, in some inflammatory conditions like rheumatoid arthritis (RA) the in vivo effect seemed to be moderate. As most TKIs are taken up actively into cells by cell membrane transporters, this study aimed to evaluate the role of such transporters for  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

&AllPage.SpinnerRetrieving;

Find a copy online

Links to this journal/publication

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Document Type: Article
All Authors / Contributors: C Schmidt-Lauber Affiliation: Experimental Nephrology, Department of Internal Medicine D, University Hospital Münster, Münster, Germany.; S Harrach; T Pap; M Fischer; M Victor; M Heitzmann; U Hansen; M Fobker; SM Brand; A Sindic; H Pavenstädt; B Edemir; E Schlatter; J Bertrand; G Ciarimboli
Language Note: English
Unique Identifier: 825941754
Awards:

Abstract:

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are effective in treating malignant disorders and were lately suggested to have an impact on non-malignant diseases. However, in some inflammatory conditions like rheumatoid arthritis (RA) the in vivo effect seemed to be moderate. As most TKIs are taken up actively into cells by cell membrane transporters, this study aimed to evaluate the role of such transporters for the accumulation of the TKI Imatinib mesylates in RA synovial fibroblasts as well as their regulation under inflammatory conditions. METHODOLOGY/PRINCIPAL FINDINGS: The transport and accumulation of Imatinib was investigated in transporter-transfected HEK293 cells and human RA synovial fibroblasts (hRASF). Transporter expression was quantified by qRT-PCR. In transfection experiments, hMATE1 showed the highest apparent affinity for Imatinib among all known Imatinib transporters. Experiments quantifying the Imatinib uptake in the presence of specific transporter inhibitors and after siRNA knockdown of hMATE1 indeed identified hMATE1 to mediate Imatinib transport in hRASF. The anti-proliferative effect of Imatinib on PDGF stimulated hRASF was quantified by cell counting and directly correlated with the uptake activity of hMATE1. Expression of hMATE1 was investigated by Western blot and immuno-fluorescence. Imatinib transport under disease-relevant conditions, such as an altered pH and following stimulation with different cytokines, was also investigated by HPLC. The uptake was significantly reduced by an acidic extracellular pH as well as by the cytokines TNFα, IL-1β and IL-6, which all decreased the expression of hMATE1-mRNA and protein. CONCLUSION/SIGNIFICANCE: The regulation of Imatinib uptake via hMATE1 in hRASF and resulting effects on their proliferation may explain moderate in vivo effects on RA. Moreover, our results suggest that investigating transporter mediated drug processing under normal and pathological conditions is important for developing intracellular acting drugs used in inflammatory diseases.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/825941754> # Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis.
    a schema:Article, schema:CreativeWork ;
    library:oclcnum "825941754" ;
    rdfs:comment "949 $l Research Support, Non-U.S. Gov't" ;
    rdfs:comment "949 $l Journal Article" ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/victor_m> ; # Victor M
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/pap_t> ; # Pap T
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/edemir_b> ; # Edemir B
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/hansen_u> ; # Hansen U
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/fobker_m> ; # Fobker M
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/sindic_a> ; # Sindic A
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/fischer_m> ; # Fischer M
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/harrach_s> ; # Harrach S
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/brand_sm> ; # Brand SM
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/bertrand_j> ; # Bertrand J
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/schlatter_e> ; # Schlatter E
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/heitzmann_m> ; # Heitzmann M
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/ciarimboli_g> ; # Ciarimboli G
    schema:contributor <http://experiment.worldcat.org/entity/work/data/1192106335#Person/pavenstadt_h> ; # Pavenstädt H
    schema:creator <http://experiment.worldcat.org/entity/work/data/1192106335#Person/schmidt_lauber_c> ; # Schmidt-Lauber C
    schema:description "METHODOLOGY/PRINCIPAL FINDINGS: The transport and accumulation of Imatinib was investigated in transporter-transfected HEK293 cells and human RA synovial fibroblasts (hRASF). Transporter expression was quantified by qRT-PCR. In transfection experiments, hMATE1 showed the highest apparent affinity for Imatinib among all known Imatinib transporters. Experiments quantifying the Imatinib uptake in the presence of specific transporter inhibitors and after siRNA knockdown of hMATE1 indeed identified hMATE1 to mediate Imatinib transport in hRASF. The anti-proliferative effect of Imatinib on PDGF stimulated hRASF was quantified by cell counting and directly correlated with the uptake activity of hMATE1. Expression of hMATE1 was investigated by Western blot and immuno-fluorescence. Imatinib transport under disease-relevant conditions, such as an altered pH and following stimulation with different cytokines, was also investigated by HPLC. The uptake was significantly reduced by an acidic extracellular pH as well as by the cytokines TNFα, IL-1β and IL-6, which all decreased the expression of hMATE1-mRNA and protein." ;
    schema:description "BACKGROUND: Tyrosine kinase inhibitors (TKIs) are effective in treating malignant disorders and were lately suggested to have an impact on non-malignant diseases. However, in some inflammatory conditions like rheumatoid arthritis (RA) the in vivo effect seemed to be moderate. As most TKIs are taken up actively into cells by cell membrane transporters, this study aimed to evaluate the role of such transporters for the accumulation of the TKI Imatinib mesylates in RA synovial fibroblasts as well as their regulation under inflammatory conditions." ;
    schema:description "CONCLUSION/SIGNIFICANCE: The regulation of Imatinib uptake via hMATE1 in hRASF and resulting effects on their proliferation may explain moderate in vivo effects on RA. Moreover, our results suggest that investigating transporter mediated drug processing under normal and pathological conditions is important for developing intracellular acting drugs used in inflammatory diseases." ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/1192106335> ;
    schema:isPartOf <http://worldcat.org/issn/1932-6203#7_12> ;
    schema:name "Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis." ;
    schema:pageStart "e52247" ;
    schema:productID "825941754" ;
    schema:sameAs <http://dx.doi.org/10.1371/journal.pone.0052247> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/825941754> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/1192106335#Person/schmidt_lauber_c> # Schmidt-Lauber C
    a schema:Person ;
    schema:name "Schmidt-Lauber C" ;
    .

<http://worldcat.org/issn/1932-6203>
    a schema:Periodical ;
    rdfs:label "PloS one" ;
    schema:issn "1932-6203" ;
    .

<http://www.worldcat.org/title/-/oclc/825941754>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/825941754> ; # Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis.
    schema:dateModified "2017-08-11" ;
    void:inDataset <http://purl.oclc.org/dataset/medline> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.